Observational studyBMC ophthalmology2025
Effect of combined therapy based on transscleral peripheral retinal cryotherapy in the treatment of open-angle neovascular glaucoma: a retrospective study.
Observational study in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsThis study aims to describe and evaluate the efficacy of transscleral peripheral retinal cryotherapy (TPRC) combined with other intraocular pressure (IOP)-lowering treatments in patients with open-angle neovascular glaucoma (NVG).
methodsA retrospective observational case series was conducted, including 16 eyes from 16 patients with open-angle NVG, treated with combinations of TPRC and IOP-lowering eyedrops, TPRC and cyclocryotherapy, or TPRC and transscleral ciliary photocoagulation (TCP) over a 4-year period (01/2020-01/2024). Preoperative, intraoperative data, and postoperative data at day 1, week 1, and months 1, 6, and 12 were systematically collected.
resultsThe primary causes of NVG were proliferative diabetic retinopathy (68.75%) and central retinal vein occlusion (31.25%). The mean (± SD) pre-treatment IOP was 36.56 ± 6.73 mmHg, decreasing to 14.81 ± 2.59 mmHg at 12 months of follow-up. The mean (± SD) best-corrected visual acuity (BCVA) in LogMAR was 2.25 ± 0.8 at baseline, improving to 1.81 ± 0.50 at 12 months. All patients demonstrated a reduction in iris neovascularization following TPRC. No serious complications were observed.
conclusionsTPRC-based IOP-lowering combination therapies appear to be an effective treatment option for open-angle NVG. These approaches may be particularly suitable for primary healthcare settings, hospitals without advanced glaucoma surgery capabilities, or NVG patients with limited economic resources and extremely elevated IOP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.